Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 3

recruiting
3 974
countries
28
conditions
2 106

30 trials match your criteria

Macular telangiectasia

Not recruiting

Study Comparing Aflibercept and Placebo for Patients with Macular Telangiectasia Type 1

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept

Diabetic retinal oedema+4

Not recruiting

Study on the Safety and Use of AVT06 (Aflibercept) for Patients with Chorioretinal Vascular Diseases

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept

Retinopathy of prematurity

Not recruiting

Long-Term Study on Aflibercept for Retinopathy of Prematurity in Infants

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Aflibercept

Colorectal cancer metastatic

Not recruiting

Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib

Macular oedema+1

Not recruiting

Study on the Effectiveness and Safety of Aflibercept for Patients with Vision Loss Due to Macular Edema from Retinal Vein Blockage

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept

Neovascular age-related macular degeneration

Not recruiting

Study Comparing Bevacizumab and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.